Topotecan
Product Images NDC 71288-127

4 FDA label images from Meitheal Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topotecan (NDC 71288-127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Top0c 0001 01)

Structural Formula (Top0c 0001 01)
Chemical structure of Topotecan showing its molecular configuration, including a lactone ring and a dimethylamino group as part of its structure.*
FDA Label Image

Figure 1 (Top0c 0001 02)

Figure 1 (Top0c 0001 02)
A survival curve chart comparing Topotecan Hydrochloride with Cisplatin versus Cisplatin Monotherapy, showing the proportion surviving over months on study. The chart includes number at risk data for both treatment groups at various time points up to 40 months.*
FDA Label Image

Principal Display Panel – Topotecan Hydrochloride For Injection 4 mg Vial Label (Top0c 0001 03)

Principal Display Panel – Topotecan Hydrochloride For Injection 4 mg Vial Label (Top0c 0001 03)
Topotecan Hydrochloride for Injection 4 mg (base) per vial from Meitheal Pharmaceuticals Inc. This packaging label indicates the product is lyophilized, must be diluted, and intended for intravenous use. It highlights that topotecan hydrochloride is cytotoxic, preservative-free, and not made with natural rubber latex. Storage conditions and handling precautions are also noted.*
FDA Label Image

Principal Display Panel (Topotecan Hydrochloride for Injection 4 mg Carton)

Principal Display Panel (Topotecan Hydrochloride for Injection 4 mg Carton)
Packaging label for Topotecan Hydrochloride for Injection 4 mg (base) per vial by Meitheal Pharmaceuticals Inc. The label indicates the drug is lyophilized, must be diluted, for intravenous use, and is a cytotoxic agent. The label includes storage instructions, inactive ingredients, and a barcode along with the Rx only symbol and Meitheal logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.